MabVax Therapeutics Files Suit Against Sichenzia Ross Ference LLP, a Law Firm that Formerly Represented the Company in Certain Corporate, Securities, and Securities and Exchange Commission Matters Sep 11, 2018
MabVax Therapeutics and Boehringer Ingelheim Sign Asset Purchase and License Agreement and Related Agreements for an Antibody Development Program Targeting Multiple Solid Tumor Cancers Jul 9, 2018
MabVax Therapeutics' HuMab-5B1 ImmunoPET Imaging Agent MVT-2163 Subject of National Institutes of Health R01 Research Grant Awarded to Memorial Sloan Kettering Cancer Center Jul 6, 2018
